

**Institutional review board statement:** Ethics approval for this study was obtained from the Biomedical Panel of the University of Alberta Health Research Ethics Board (Pro00001371).

308 Campus Tower  
University of Alberta, Edmonton, AB T6G 1K8  
p. 780.492.9724 (Biomedical Panel)  
p. 780.492.0302 (Health Panel)  
p. 780.492.0459  
p. 780.492.0839  
f. 780.492.7808

### Notification Re-approval

Date: May 29, 2009

Principal Investigator: [Michael Clandinin](#)

Renewal ID: [Pro00001371\\_REN1](#)

Study ID: [Pro00001371](#)

Study Title: Milk-derived gangliosides as novel anti-inflammatory therapy for inflammatory bowel disease

Approval  
Expiry Date: May 28, 2010

Thank you for returning the request for re-approval of this study. The Health Research Ethics Board (Biomedical Panel) has reviewed the file on this project for which all documentation is currently up-to-date. The research has been found to be acceptable within the limitations of human experimentation.

#### Specific Comments

The expiration date for this approval is noted above. A renewal report or closure report must be submitted next year prior to the expiry of this approval. You will receive electronic reminders at 60, 30, 15 and 1 day(s) prior to the expiry date. If you do not renew on or before that date, you will have to submit a new ethics application.

For studies where investigators must obtain informed consent, signed copies of the consent form must be retained, as should all study related documents, so as to be available to the HREB on request. They should be kept for the duration of the project and for at least seven years following its completion. In the case of clinical trials approved under Division 5 of the Food and Drug regulations of Health Canada, study records must be retained for 25 years.

Sincerely,

S.K.M. Kimber, MD, FRCPC  
Chair, Health Research Ethics Board (Biomedical Panel)

*Note: This correspondence includes an electronic signature (validation and approval via an online system).*

